Sterling Biotech Limited reported unaudited standalone earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported net sales/income from operations was INR 1,070.344 million against INR 1,727.508 million for the same period in the last year. Loss from operations before other income and finance costs was INR 553.394 million against INR 360.64 million a year ago. Loss from ordinary activities after finance costs before tax was INR 1,394.591 million against INR 1,646.434 million for the same period in the last year. Net loss from ordinary activities after tax, net loss for the quarter was INR 942.091 million or INR 2.18 per diluted share after extraordinary items against INR 1,112.234 million or INR 2.57 per diluted share before and after extraordinary items for the same period in the last year.

For the nine months, the company reported net sales/income from operations was INR 3,245.6 million against INR 5,453.225 million for the same period in the last year. Loss from operations before other income and finance costs was INR 1,614.886 million against INR 893.061 million a year ago. Loss from ordinary activities after finance costs before tax was INR 4,041.723 million against INR 4,712.135 million for the same period in the last year. Net loss from ordinary activities after tax, net loss for the period was INR 2,730.323 million or INR 6.31 per diluted share after extraordinary items against INR 3,183.235 million or INR 7.35 per diluted share before and after extraordinary items for the same period in the last year.